Brief: Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer Trial

Apogee Therapeutics

03/03/2025 11:10

March 3 (Reuters) - Apogee Therapeutics APGE.O:

APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 1 RESULTS FROM THE APG990 HEALTHY VOLUNTEER TRIAL, UNLOCKING POTENTIAL MAINTENANCE DOSING EVERY THREE AND SIX MONTHS FOR APG279 (APG777 + APG990)

APOGEE THERAPEUTICS INC - APG990 WELL TOLERATED UP TO 1,200MG DOSES

APOGEE THERAPEUTICS INC - MOST COMMON ADVERSE EVENT FOR APG990 WAS HEADACHE

APOGEE THERAPEUTICS INC - NO SEVERE ADVERSE EVENTS OR STUDY DISCONTINUATIONS FOR APG990

APOGEE THERAPEUTICS INC - TO INITIATE PHASE 1B TRIAL OF APG279 AGAINST DUPIXENT IN 2025

Source text: ID:nGNX4V8GW9

Further company coverage: APGE.O

 ((Reuters.Briefs@thomsonreuters.com;))